Bifunktionalisierte Antikörperkonjugate gegen den Endothelinrezeptor B

Details

Veröffentlichungs-Nr.

EP4721765

Anmeldetag

4. Oktober 2024

Veröffentlichung

8. April 2026

Rechtsraum

EP

IPC

(GENENTECH INC et al.)(GONCALVES VICTOR et al.)(ARARIS BIOTECH AG et al.)(BOQUET DIDIER et al.)

Abstract

The present invention relates to novel antibody conjugates containing chimeric or humanized antibodies (or fragments thereof) that are able to recognize specifically the human Endothelin B receptors expressed on tumor cells, said antibodies or fragments carrying at least two functional molecules that are cytotoxic and / or detectable. The invention also relates to the use of such bifunctionalized antibody conjugates as diagnostic agents and/or as medicaments, for detecting and/or treating patients suffering from melanoma and other cancers in which the human endothelin B receptor is overexpressed, such as glioblastoma, bladder cancer, lung cancer, kidney cancer, or vulvar cancer.

Anmelder

Firmen

Commissariat à l'Energie Atomique et aux Energies Alternatives
Université de Bourgogne
Université Paris-Saclay
Centre National de la Recherche Scientifique
Institut National de la Recherche pour l'Agriculture, l'Alimentation et l'Environnement

Land

🇫🇷 Frankreich